Glimzab MV 2mg/500mg/0.3mg Tablet ER
Marketer
Neucure Lifesciences Private Limited
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Glimzab MV 2mg/500mg/0.3mg Tablet ER
Glimzab MV 2mg/500mg/0.3mg Extended-Release tablets are classified as antidiabetic medications. This combination therapy is indicated for adult patients with type 2 diabetes mellitus to manage blood glucose control. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage will be determined by your physician and may be adjusted based on your glycemic response. Continuous use is crucial, even with well-controlled blood sugar, as discontinuation without medical supervision can elevate glucose levels, potentially leading to complications like nephropathy, retinopathy, neuropathy, and limb loss. Remember, this medication forms part of a comprehensive treatment plan encompassing a healthy diet, regular physical activity, and weight management as directed by your doctor. Lifestyle modifications significantly influence diabetes control. Hypoglycemia (low blood sugar) is the most prevalent adverse effect. Learn to identify its symptoms (sweating, dizziness, headache, tremors) and appropriate management strategies. Maintaining consistent mealtimes and carrying a readily available fast-acting glucose source (e.g., sugary snacks or juice) are preventative measures. Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Other possible side effects include altered taste perception, nausea, diarrhea, abdominal discomfort, cephalalgia, edema, visual blurring, bone fractures, and upper respiratory infections. Weight gain may occur in some individuals. This medication is contraindicated in patients with type 1 diabetes mellitus, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before commencing treatment, as it may influence suitability. Pregnant or lactating women should consult their physician prior to use. Regular blood glucose monitoring is necessary, and your doctor might recommend blood tests to assess blood cell counts and liver function.
Primary Ingredients of Glimzab MV 2mg/500mg/0.3mg Tablet ER
No information provided. Please provide the text you wish to be rewritten.
Uses of Glimzab MV 2mg/500mg/0.3mg Tablet ER
Managing Type 2 diabetes
Major Benefits of Glimzab MV 2mg/500mg/0.3mg Tablet ER:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the entire tablet without chewing, crushing, or breaking it. Take Glimzab MV 2mg/500mg/0.3mg Extended-Release Tablets on an empty stomach.
Common Side effects of Glimzab MV 2mg/500mg/0.3mg Tablet ER:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Glimzab MV 2mg/500mg/0.3mg Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Glimzab MV 2mg/500mg/0.3mg Extended-Release tablet whole; do not chew, crush, or divide it. Administer this medication on an empty stomach.
How Glimzab MV 2mg/500mg/0.3mg Tablet ER works:
Extended-release Glimzab MV tablets (2mg/500mg/0.3mg) contain a triple-drug formulation for diabetes management.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glimzab MV 2mg/500mg/0.3mg Tablet ER with alcohol is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The extended-release Glimzab MV 2mg/500mg/0.3mg tablet might pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Glimzab MV 2mg/500mg/0.3mg tablet is likely unsafe for breastfeeding mothers. Available human data indicate potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
Extended-release Glimzab MV 2mg/500mg/0.3mg tablets are likely unsafe for individuals with kidney impairment and should be omitted. Medical advice is recommended. Furthermore, Glimzab MV 2mg/500mg/0.3mg extended-release tablets are contraindicated in patients exhibiting severe kidney disease.
LiverCAUTION
Patients with liver impairment should use Glimzab MV 2mg/500mg/0.3mg Extended-Release tablets cautiously. Dosage modifications may be necessary. Physician consultation is advised. For individuals with mild to moderate liver disease, initiation should be at a low dose; use is contraindicated in those with severe hepatic dysfunction.
What if you forget to take Glimzab MV 2mg/500mg/0.3mg Tablet ER :
Should you forget to take your Glimzab MV 2mg/500mg/0.3mg Extended-Release Tablet, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glimzab MV 2mg/500mg/0.3mg Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently